11/03/2023

Tempus Announces New ctDNA Assay, xM Monitor

Tumor uninformed treatment response monitoring assay for research use only

Tempus, a leader in artificial intelligence and precision medicine, today announced xM Monitor (formerly xF Monitor) – a new circulating tumor DNA (ctDNA) assay for research use only, which detects and monitors changes in circulating tumor fraction to determine early response to immunotherapy for patients with advanced cancers. 

Tempus’ xM Monitor assay measures quantitative molecular changes in ctDNA tumor fraction by utilizing diverse genomic events, dynamically weighting somatic variant allele frequencies and copy number variants, while using germline information to inform these estimates. The algorithm that powers xM Monitor – ctDNA tumor fraction – utilizes multiple single input models and weights their importance based on failure modes observed in Tempus’ multimodal database. The Tempus team will debut the xM Monitor assay at the Society for Immunotherapy of Cancer’s 38th Annual Meeting this week. 

“We are excited to add the xM Monitor assay to our comprehensive suite of precision medicine offerings here at Tempus,” said Kate Sasser, PhD, Chief Scientific Officer at Tempus. “There has been tremendous progress in the utilization of ctDNA for monitoring patient response to treatment, especially for immunotherapy. We are looking forward to bringing our xM Monitor assay forward as a diagnostic tool to help biopharma develop innovative medicines and physicians to tailor therapies for patients.”

xM Monitor is now available for research use only for both Tempus’ 105-gene liquid assay, xF, and Tempus’ 523-gene liquid assay, xF+. 

About Tempus

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.

Related Content

View more
  • post image
    02/13/2025

    AI & ML in action: Real-time advances in precision medicine

    Explore the capabilities of the Tempus platform, where cutting-edge diagnostics meet actionable data insights to enhance precision medicine. Learn how AI and ML tools seamlessly integrate biomarkers into the diagnostic process, ensuring patients receive the right treatment(s) at the right time. Experience Tempus Lens in action, with an exclusive live demonstration of our newest AI advancements, and hear perspectives on AI's expanding role in healthcare and its transformative potential.

    Watch replay
  • post image
    01/27/2025

    Addressing health disparities at a large academic medical center: AI-driven cardiac care for aortic stenosis and mitral regurgitation

    Leveraging a natural language processing (NLP) based, artificial intelligence (AI) driven protocol, Tempus Next worked to help clinicians improve management of patients with severe aortic stenosis (sAS) and severe mitral regurgitation (sMR) by identifying patients who may have been previously overlooked.

    Read more
  • post image
    12/05/2024

    Advancing IO therapeutics: The convergence of novel biomarkers and combination strategies

    Explore the latest in immuno-oncology (IO), where emerging therapies are reshaping the landscape of cancer treatment. This webinar will focus on the role of novel biomarkers and combination treatment strategies in understanding and enhancing the immune system's response to cancer. Discover the significant developments that are helping to shape clinical trials and improving patient outcomes in IO and hear perspectives from industry experts on the potential of emerging therapies.

    Watch replay